Ganglioside biosynthesis modulators
AssigneeZacharon Pharmaceuticals, Inc.
InventorsBrett E. CRAWFORD, Charles A. GLASS, Jillian R. BROWN, Xiaomei BAI
Life of this patent
Estimating the term…
Abstract
Provided herein are ganglioside synthesis inhibitors, including modulators of ganglioside glycosylation.
Claims20
A process for modifying the cellular population of a ganglioside, the process comprising contacting a cell having at least one ganglioside with an effective amount of a selective late-stage ganglioside biosynthesis inhibitor, the selective ganglioside biosynthesis inhibitor being active in a mammalian cell.
A composition comprising a population of human serum gangliosides, the population comprising less than 34 mol. % α 2,8-linked sialic acid containing gangliosides.
A composition comprising a population of human serum gangliosides, the population comprising greater than 3 mol. % O series gangliosides.
A composition comprising a population of human serum gangliosides, the population comprising less than 15 mol. % (β1,3) linked galactose containing gangliosides.
A composition comprising a population of human serum gangliosides, the population comprising less than 23 mol. % of (β1,4) linked GalNac gangliosides.
Dependencies are inferred from the claim text.